Drug intelligence / Profile preview

FEN164

Development stage: Unknown
Lead developer: Fenix Innovation Group
Modality: Small Molecules
Administration: Oral

Overview

FEN164 is a full-spectrum medicinal cannabis plant extract containing less than 0.08% THC, developed for the treatment of Autism Spectrum Disorder (ASD) in children. It is administered orally as an oil. The product contains newly discovered rarer cannabinoids CBDP and CBDB, which have shown to reduce inflammation within brain cells and have more potency than CBD isolate alone in in vitro studies. FEN164 has also demonstrated increased neuro-regulatory and neuro-modulatory activities with no negative effects on cell health.

Other names: Full-Spectrum Medicinal Cannabis Plant Extract

Targets

PPARG (Peroxisome proliferator-activated receptor gamma)CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on FEN164.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FEN164.

Explore the full profile